Common Epilepsy Drug Could Prevent And Treat Alzheimer's Disease
October 28, 2008
Adapted from the University of British Columbia
A research team led by University of British Columbia (UBC) Psychiatry Professor Weihong Song, found that memory deficits are reversed if valproic acid (VPA) is used as a treatment in the early stages of Alzheimer's disease (AD). The study, published in the Journal of Experimental Medicine, reveals that VPA works by inhibiting the activity of an enzyme that produces a neurotoxic protein called beta-amyloid. In doing so, plaque formation is discontinued. Beta-amyloid proteins are the central component of neurotoxic plaques in AD.
"We found that if we used VPA in the early stage of Alzheimer's disease, in model mice, it reduced plaque formation and further prevented brain cell death and axon damage," says Song, who is a Canada Research Chair in Alzheimer's disease and Director of the Townsend Family Laboratories in UBC's Faculty of Medicine. "The drug also improved performance in memory tests." The results will help inform the design of human clinical trials because researchers now understand the mechanisms and pathology of VPA in AD animal models.
"We are very excited about these results because we now know when VPA should be administered to be most effective and we now know how VPA is working to prevent AD," says Song, who is also a member of the Brain Research Centre at UBC. "A small human clinical trial is currently underway and we expect results to be available in the next year."
View all news updates for Alzheimer's disease
Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.